Diamond Equity Research Releases Update Note on Arovella Therapeutics Limited (ASX: ALA)

August 5, 2022

/EIN News/ -- NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released update note on Arovella Therapeutics Limited (ASX: ALA). The update note includes information on the Arovella Therapeutics’ financial results, management commentary, recent developments, outlook, risks, and our revised valuation estimates.

The update note is available here. Highlights from the note include:

About Arovella Therapeutics Limited

Arovella Therapeutics is a Biotechnology company that reformulates existing drugs for oro-mucosal administration and has recently licensed novel cancer immunotherapies in early development phase. The company is targeting certain disease areas and developing therapies that help people to live longer and healthier lives.

For more information, visit https://www.arovella.com/

About Diamond Equity Research

Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on major institutional investor platforms including Factset, Morningstar, and Thomson One.

For more information, visit https://www.diamondequityresearch.com.

Disclosures:

Diamond Equity Research LLC is being compensated by Arovella Therapeutics Limited for producing research materials regarding Arovella Therapeutics Limited, and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however, the views in the report reflect that of Diamond Equity Research. As of 08/05/2022 the issuer had paid us $33,000 for our company sponsored research services, which commenced 11/11/2021 and is billed annually. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed $5,000. The issuer has paid us for non-research related services as of 08/05/22 consisting of $2,500 for presenting at an investment conference. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then. Although Diamond Equity Research company sponsored reports are based on publicly available information and although no investment recommendations are made within our company sponsored research reports, given the small capitalization nature of the companies we cover we have adopted an internal trading procedure around the public companies by whom we are engaged, with investors able to find such policy on our website public disclosures page. This report and press release do not consider individual circumstances and does not take into consideration individual investor preferences. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in small capitalization equities including the complete loss of their investment. Investors can find various risk factors in the initiation report and in the respective financial filings for Arovella Therapeutics Limited.

Contact:

Diamond Equity Research
research@diamondequityresearch.com